Skip to main content
SpringerLink
Log in

Changes in Toxicity and Effectiveness with Timing of Drug Administration

Implications for Drug Safety

  • Current Opinion
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

The effectiveness and toxicity of many drugs can vary depending on the time of administration in relation to 24-hour rhythms of biochemical, physiological and behavioural processes under the control of the circadian clock. Such chronopharmacological phenomena are influenced by not only the pharmacokinetics but also pharmacodynamics of medications. Chronotherapy is especially relevant when the risk and/or intensity of the symptoms of disease vary predictably over time as exemplified by allergic rhinitis, arthritis, asthma, myocardial infarction, congestive heart failure, stroke and peptic ulcer disease. Morning, once-daily administration of corticosteroids results in little adrenocortical suppression, while the same daily dose split into four equal doses to coincide with daily meals and bedtime results in significant hypothalamus-pituitary-adrenal axis suppression. In a randomised, multicentre trial involving patients with previously untreated metastases from colorectal cancer, the chronomodulated infusion of oxaliplatin, fluorouracil and folinic acid was compared with a constant-rate infusion method. Adverse effects such as stomatitis and peripheral sensory neuropathy were lower and objective response was higher with chronotherapy as compared with the fixed-rate infusion. The merit of chronomodulated infusion is supported by the 24-hour rhythm of DNA synthesis and the activity of dehydropyrimidine dehydrogenase, which brings about the intracellular catabolism of fluorouracil. On the other hand, haloperidol and selective serotonin reuptake inhibitors have diverse effects on sleep continuity and nocturnal arousals. Although interferon also alters the clock function, this disruptive effect can be overcome by devising an administration regimen that minimises adverse drug effects on clock function. Thus, one approach to increasing the efficiency of pharmacotherapy is the administration of drugs at times at which they are most effective and/or best tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ozdemir V, Shear NH, Kalow W. What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? Drug Saf 2001; 24(2): 75–85

    Article  PubMed  CAS  Google Scholar 

  2. Halberg F. Chronobiology. Annu Rev Physiol 1969; 31: 675–725

    Article  PubMed  CAS  Google Scholar 

  3. Reinberg A, Halberg F. Circadian chronopharmacology. Annu Rev Pharmacol 1971; 11: 455–92

    Article  PubMed  CAS  Google Scholar 

  4. Labrecque G, Belanger PM. Biological rhythms in the absorption, distribution, metabolism and excretion of drugs. Pharmacol Ther 1991; 52: 95–107

    Article  PubMed  CAS  Google Scholar 

  5. Haus E, Touittou Y. Chronobiology of development and aging. In: Redfern PH, Lemmer B, editors. Physiology and pharmacology of biological rhythms. Berlin, Heidelberg: Springer-Verlag, 1997: 95–134

    Google Scholar 

  6. Smolensky MH, Labrecque G. Chronotherapeutics. Pharmaceutical News 1997; 4: 10–6

    Google Scholar 

  7. Duncan WC. Circadian rhythms and the pharmacology of affective illness. Pharmacol Ther 1996; 71: 253–312

    Article  PubMed  CAS  Google Scholar 

  8. Moore RY, Eichler VB. Loss of a circadian adrenal corticosterone rhythm following suprachiasmatic lesions in the rat. Brain Res 1972; 42: 201–6

    Article  PubMed  CAS  Google Scholar 

  9. Tei H, Okamura H, Shigeyoshi Y, et al. Circadian oscillation of a mammalian homologue of the Drosophila period gene. Nature 1997; 389: 512–6

    Article  PubMed  CAS  Google Scholar 

  10. Chang DC, Reppert SM. The circadian clocks of mice and men. Neuron 2001; 29: 555–8

    Article  PubMed  CAS  Google Scholar 

  11. Sakamoto K, Nagase T, Fukui H, et al. Multitissue circadian expression of rat period homolog (rPer2) mRNA is governed by the mammalian circadian clock, the suprachiasmatic nucleus in the brain. J Biol Chem 1998; 273: 27039–42

    Article  PubMed  CAS  Google Scholar 

  12. Jin X, Shearman LP, Weaver DR, et al. A molecular mechanism regulating rhythmic output from the suprachiasmatic circadian clock. Cell 1999; 96: 57–68

    Article  PubMed  CAS  Google Scholar 

  13. Ueyama T, Krout KE, Nguyen XV, et al. Suprachiasmatic nucleus: a central autonomic clock. Nat Neurosci 1999; 2: 1051–3

    Article  PubMed  CAS  Google Scholar 

  14. Silver R, LeSauter J, Tresco PA, et al. A diffusible coupling signal from the transplanted suprachiasmatic nucleus controlling circadian locomotor rhythms. Nature 1996; 382: 810–3

    Article  PubMed  CAS  Google Scholar 

  15. Mrosovsky N. Problems in interpreting the effects of drugs on circadian rhythms. In: Redfern PH, Lemmer B, editors. Physiology and pharmacology of biological rhythms. Berlin, Heidelberg: Springer-Verlag, 1997: 415–34

    Google Scholar 

  16. Moore RY. Chemical neuroanatomy of the mammalian circadian system. In: Redfern PH, Lemmer B, editors. Physiology and pharmacology of biological rhythms. Berlin, Heidelberg: Springer-Verlag, 1997: 79–93

    Google Scholar 

  17. Shigeyoshi Y, Taguchi K, Yamamoto S, et al. Light-induced resetting of a mammalian circadian clock is associated with rapid induction of the mPer1 transcript. Cell 1997; 91: 1043–53

    Article  PubMed  CAS  Google Scholar 

  18. Ohdo S, Ogawa N, Nakano S, et al. Influence of feeding schedule on the chronopharmacological aspects of sodium valproate in mice. J Pharmacol Exp Ther 1996; 278: 74–81

    PubMed  CAS  Google Scholar 

  19. Jones CR, Campbell SS, Zone SE, et al. Familial advanced sleep-phase syndrome: a short-period circadian rhythm variant in humans. Nat Med 1999; 5: 1062–5

    Article  PubMed  CAS  Google Scholar 

  20. Lewy AJ. Melatonin as a marker and phase-resetter of circadian rhythms in humans. In: Olcese J, editor. Melatonin after four decades: an assessment of its potentia. New York: Kluwer Academic/Plenum Publishers, 1999: 425–34

    Google Scholar 

  21. Akiyama M, Kouzu Y, Takahashi S, et al. Inhibition of light- or glutamate-induced mPer1 expression represses the phase shifts into the mouse circadian locomotor and suprachiasmatic firing rhythms. J Neurosci 1999; 19: 1115–21

    PubMed  CAS  Google Scholar 

  22. Horikawa K, Yokota S, Fuji K, et al. Nonphotic entrainment by 5-HT1A/7 receptor agonists accompanied by reduced Per1 and Per2 mRNA levels in the suprachiasmatic nuclei. J Neurosci 2000; 20: 5867–73

    PubMed  CAS  Google Scholar 

  23. Ceresa F, Angeli A, Boccuzzi A, et al. Once-a-day neurally stimulated and basal ACTH secretion phases in man and their responses to corticoid inhibition. J Clin Endocrinol Metab 1969; 29: 1074–82

    Article  PubMed  CAS  Google Scholar 

  24. Smolensky MH, D’Alozo GE. Progress in the chronotherapy of nocturnal asthma. In: Redfern PH, Lemmer B, editors. Physiology and pharmacology of biological rhythms. Berlin, Heidelberg: Springer-Verlag, 1997: 205–49

    Google Scholar 

  25. Reinberg A, Smolensky MH, D’Alonzo GE, et al. Chronobiology and asthma: III. Timing corticotherapy to biological rhythms to optimize treatment goals. J Asthma 1988; 25: 219–48

    Article  PubMed  CAS  Google Scholar 

  26. Reinberg A. Chronopharmacology of corticosteroids and ACTH. In: Lemmer B, editor. Chronopharmacology: cellular and biochemical interactions. New York: Marcel Dekker, 1989: 137–78

    Google Scholar 

  27. Levy F. Circadian chronotherapy for human cancers. Lancet Oncol 2001; 2: 307–15

    Article  Google Scholar 

  28. Levy F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer: International Organization for Cancer Chronotherapy. Lancet 1997; 350: 681–6

    Article  Google Scholar 

  29. Hrushesky WJM. Circadian timing of cancer chemotherapy. Science 1985; 228: 73–5

    Article  PubMed  CAS  Google Scholar 

  30. Ohdo S, Makinosumi T, Ishizaki T, et al. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J Pharmacol Exp Ther 1997; 283: 1383–8

    PubMed  CAS  Google Scholar 

  31. Takane H, Ohdo S, Yamada T, et al. Chronopharmacology of antitumor effect induced by interferon-β in tumor-bearing mice. J Pharmacol Exp Ther 2000; 294: 746–52

    PubMed  CAS  Google Scholar 

  32. Dagan Y. Circadian rhythm sleep disorders (CRSD) in psychiatry: a review. Isr J Psychiatry Relat Sci 2002; 39(1): 19–27

    PubMed  Google Scholar 

  33. Wirz-Justice A, Cajochen C, Nussbaum P. A schizophrenic patient with an arrhythmic circadian rest-activity cycle. Psychiatry Res 1997; 73: 83–90

    Article  PubMed  CAS  Google Scholar 

  34. Dagan Y. Sleep wake schedule disorders as a possible side effect of CNS medications [abstract]. Chronobiol Int 1999; 16: 25

    Article  Google Scholar 

  35. Wirz-Justice A, Werth E, Savaskan E, et al. Haloperidol disrupts, clozapine reinstates the circadian rest-activity cycle in a patient with early-onset Alzheimer disease. Alzheimer Dis Assoc Disord 2000 Oct-Dec; 14: 212–215

    Article  PubMed  CAS  Google Scholar 

  36. Ayalon L, Hermesh H, Dagan Y. Case study of circadian rhythm sleep disorder following haloperidol treatment: reversal by risperidone and melatonin. Chronobiol Int 2002; 19(5): 947–59

    Article  PubMed  Google Scholar 

  37. Hermesh H, Lemberg H, Abadi J, et al. Circadian rhythm sleep disorders (CRSD) as a possible side effect of fluvoxamine. CNS Spectr 2001; 6: 511–3

    PubMed  CAS  Google Scholar 

  38. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38–47

    Article  PubMed  CAS  Google Scholar 

  39. Janssen HL, Brouwer JT, van der Mast RC, et al. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J Hepatol 1994; 21: 241–3

    Article  PubMed  CAS  Google Scholar 

  40. Bocci V. Administration of interferon at night may increase its therapeutic index. Cancer Drug Deliv 1985; 2: 313–8

    Article  PubMed  CAS  Google Scholar 

  41. Ohdo S, Koyanagi S, Suyama H, et al. Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat Med 2001; 7: 356–60

    Article  PubMed  CAS  Google Scholar 

  42. Koyanagi S, Ohdo S. Alteration of intrinsic biological rhythms during interferon treatment and its possible mechanism. Mol Pharmacol 2002; 62: 1393–9

    Article  PubMed  CAS  Google Scholar 

  43. Hunter CA, Gabriel KE, Radzanowski T, et al. Type I interferons enhance production of IFN-γ by NK cells. Immunol Lett 1997; 59: 1–5

    Article  PubMed  CAS  Google Scholar 

  44. Lundkvist GB, Robertson B, Mhlanga JD, et al. Expression of an oscillating interferon-γ receptor in the suprachiasmatic nuclei. Neuroreport 1998; 9: 1059–63

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author has provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Division of Clinical Pharmacy, Department of Medico-Pharmaceutical Sciences, Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Maidashi, Higashi-Ku, Fukuoka, Fukuoka, 3-1-1, 812-8582, Japan

    Shigehiro Ohdo

Authors
  1. Shigehiro Ohdo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shigehiro Ohdo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ohdo, S. Changes in Toxicity and Effectiveness with Timing of Drug Administration. Drug-Safety 26, 999–1010 (2003). https://doi.org/10.2165/00002018-200326140-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200326140-00002

Keywords

Search

Navigation